The estimated Net Worth of Roy D. Baynes is at least $1.42 Million dollars as of 25 May 2023. Mr. Baynes owns over 3,534 units of Natera Inc stock worth over $1,096,638 and over the last 8 years he sold NTRA stock worth over $0. In addition, he makes $322,900 as Independent Director at Natera Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Baynes NTRA stock SEC Form 4 insiders trading
Roy has made over 4 trades of the Natera Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,534 units of NTRA stock worth $437,615 on 25 May 2023.
The largest trade he's ever made was exercising 3,534 units of Natera Inc stock on 25 May 2023 worth over $437,615. On average, Roy trades about 310 units every 35 days since 2016. As of 25 May 2023 he still owns at least 8,856 units of Natera Inc stock.
You can see the complete history of Mr. Baynes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Roy Baynes biography
Roy Baynes serves as Independent Director of the Company. Dr. Baynes has been the senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories (NYSE: MRK), a biopharmaceutical company, since December 2013. Prior to this, Dr. Baynes served as senior vice president of oncology, inflammation and respiratory therapeutics at Gilead Sciences Inc. (Nasdaq: GILD), a biotechnology company, from January 2012 to December 2013 and the vice president global development and therapeutic area head hematology oncology at Amgen Inc. (Nasdaq: AMGN), a biopharmaceutical company, from 2002 to 2012. Dr. Baynes has served as a director of Atara Biotherapeutics, Inc. (Nasdsq: ATRA), a biopharmaceutical company, since September 2018 and as a director of Retrophin, Inc. (Nasdaq: RTRX), a biopharmaceutical company, since July 2016. Dr. Baynes has an M.D. and a Ph.D. from the University of the Witwatersrand, Johannesburg, South Africa. Our board of directors believes that Dr. Baynes is qualified to serve as a director based on his extensive experience in the biopharmaceutical industry and experience on other public company boards of directors. Dr. Baynes currently serves on our nominating and corporate governance committee.
What is the salary of Roy Baynes?
As the Independent Director of Natera Inc, the total compensation of Roy Baynes at Natera Inc is $322,900. There are 16 executives at Natera Inc getting paid more, with Steven Chapman having the highest compensation of $6,200,910.
How old is Roy Baynes?
Roy Baynes is 65, he's been the Independent Director of Natera Inc since 2018. There are 1 older and 16 younger executives at Natera Inc. The oldest executive at Natera Inc is Herman Rosenman, 72, who is the Independent Director.
What's Roy Baynes's mailing address?
Roy's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.
Insiders trading at Natera Inc
Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy, and Roelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.
What does Natera Inc do?
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
What does Natera Inc's logo look like?
Complete history of Mr. Baynes stock trades at Atara Biotherapeutics Inc, Natera Inc, and Retrophin
Natera Inc executives and stock owners
Natera Inc executives and other stock owners filed with the SEC include:
-
Steven Chapman,
President, Chief Executive Officer, Director -
Robert Schueren,
Chief Operating Officer -
Michael Brophy,
Chief Financial Officer -
Matthew Rabinowitz,
Executive Chairman of the Board, Co-Founder -
Steve Leonard Chapman,
CEO, Pres & Director -
Jonathan Sheena,
Co-Founder, Chief Technology Officer, Director -
Robert A. Schueren,
Chief Operating Officer -
Steve Chapman,
CEO, Pres & Director -
Michael Brophy,
Chief Financial Officer -
Rowan Chapman,
Independent Director -
Dr. Matthew Rabinowitz Ph.D.,
Co-Founder & Exec. Chairman -
Gail Marcus,
Independent Director -
Roelof Botha,
Lead Independent Director -
Todd Cozzens,
Independent Director -
James Healy,
Independent Director -
Herman Rosenman,
Independent Director -
Roy Baynes,
Independent Director -
Jonathan Sheena,
Co-Founder & Director -
Monica Bertagnolli,
Independent Director -
Rishi Kacker,
Chief Technology Officer -
Paul Greenland,
VP of Corp. Marketing -
Dr. Ramesh Hariharan,
VP of Marketing & Medical Education -
Phil Grinnell,
VP of Sales -
Daniel Rabinowitz L.L.M., LL.M.,
Sec. & Gen. Counsel -
Eric A. Evans,
Chief Scientific Officer -
John Steuart,
Director -
John Fesko,
PRESIDENT, CHIEF BUS. OFFICER -
Creek Ventures L P Claremon...,
-
Solomon Moshkevich,
PRESIDENT, CLINICALDIAGNOSTICS -
Creek Ventures L P Claremon...,
-
Creek Ventures L P Claremon...,
-
Venture Partners Viii Lp Li...,
-
Xii Management Llcsequoia C...,
-
Daniel Rabinowitz,
SEC. AND CHIEF LEGAL OFFICER -
Herm Rosenman,
-
Brinkley Ruth Williams,